Ribose (Furanose)

Ribose (Furanose)

SCHEMBL4391869

OC[C@H]1OC(O)[C@H](O)[C@@H]1O.c1ncc2nc[nH]c2n1

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADA P00813 1/20 0.47
ADK P55263 2/20 0.40
PNP P00491 1/20 0.37
CDK1 P06493 1/20 0.36
CDK4 P11802 1/20 0.36
CCNB1 P14635 1/20 0.36
CCND1 P24385 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.34
PYGL P06737 3/20 0.34
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34
ALDH1A1 P00352 1/20 0.34
DPP4 P27487 1/20 0.33
HIF1A Q16665 1/20 0.33
MEN1 O00255 1/20 0.33
SLC28A1 O00337 1/20 0.33
MAP3K7 O43318 1/20 0.33
SLC28A2 O43868 1/20 0.33
GAPDH P04406 1/20 0.33
ADORA3 P0DMS8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
2-Aminopurine SCHEMBL5529464 0.82 LMNA (0.41) ADKPNPSMN1; SMN2LMNAPOLB
Ribose (Furanose) SCHEMBL4391872 0.78 ADA (0.41) ADAADKPNPCDK1CDK4
Ribose (Furanose) SCHEMBL27484456 0.78 ADA (0.41) ADAADKPNPCDK1CDK4
Ribose (Furanose) SCHEMBL5199714 0.78 ADA (0.41) ADAADKPNPCDK1CDK4
Ribose (Furanose) SCHEMBL9702729 0.77 ADA (0.42) ADACDK1CDK4CCNB1CCND1
Adenine SCHEMBL14636444 0.76 HIF1A (0.49) ADKSMN1; SMN2POLBDPP4HIF1A
Purine SCHEMBL29456595 0.75
Purine SCHEMBL6421376 0.75 KDM4A (0.38) SMN1; SMN2LMNAALDH1A1PI4KAPI4K2B
Purine SCHEMBL3157 0.75
Purine SCHEMBL2120547 0.75 KDM4A (0.38) SMN1; SMN2LMNAALDH1A1PI4KAPI4K2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090299049-A1 Bicyclic Compounds and Their Use REPLIZYME LIMITED (GB) 2009-12-03 US disclosed
EP-1984455-A2 BICYCLIC COMPOUNDS AND THEIR USE THE UNIVERSITY OF YORK (GB) 2008-10-29 EP disclosed
WO-2007091056-A2 BICYCLIC COMPOUNDS AND THEIR USE THE UNIVERSITY OF YORK (GB) 2007-08-16 WO disclosed
EP-0305643-B1 N-6 thienyl substituted adenosine derivatives as cardiac vasodilators WHITBY RESEARCH INC (US) 1994-01-05 EP disclosed
US-5043325-A N-6 substituted adenosine derivatives as cardiac vasodilators WHITBY RESEARCH, INC. (US) 1991-08-27 US disclosed
EP-0180614-B1 N-6 SUBSTITUTED ADENOSINE DERIVATIVES AS CARDIAC VASODILATORS Whitby Research Incorporated (US) 1990-03-07 EP disclosed
EP-0305643-A2 N-6 thienyl substituted adenosine derivatives as cardiac vasodilators Whitby Research Incorporated (US) 1989-03-08 EP disclosed
EP-0300144-A2 N-6 alkyl substituted adenosine derivatives as cardiac vasodilators Whitby Research Incorporated (US) 1989-01-25 EP disclosed
EP-0300145-A2 N-6 phenyl substituted adenosine derivatives as cardiac vasodilators Whitby Research Incorporated (US) 1989-01-25 EP disclosed
US-4728736-A HERPES VIRUS SOUTHERN RESEARCH INSTITUTE (US) 1988-03-01 US disclosed
EP-0180614-A1 N-6 SUBSTITUTED ADENOSINE DERIVATIVES AS CARDIAC VASODILATORS. NELSON RES & DEV (US) 1986-05-14 EP disclosed
WO-1985004882-A1 N-6 SUBSTITUTED ADENOSINE DERIVATIVES AS CARDIAC VASODILATORS NELSON RESEARCH AND DEVELOPMENT COMPANY (US) 1985-11-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090299049-A1 Bicyclic Compounds and Their Use ERCC4, PARP1, ERCC5 ADA 505/4885ADK 524/4885PNP 73/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.